Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Bijay Nair, John D. Shaughnessy, Yiming Zhou, Marie Astrid-Cartron, Pingping Qu, Frits Van Rhee, Elias Anaissie, Yazan Alsayed, Sarah Waheed, Klaus Hollmig, Jackie Szymonifka, Nathan Petty, Antje Hoering, Bart Barlogie

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We report on prognostic implications for postrelapse survival (PRS) of a gene expression profiling (GEP)-defined risk score at relapse available in 120 myeloma patients previously enrolled in tandem transplantation trial Total Therapy 2. Among the 71 patients with additional GEP baseline information, 3-year PRS was 71% in 40 patients with low risk present both at baseline and relapse contrasting with only 17% in 28 patients with high risk at relapse, 12 of whom with baseline low-risk status fared better than the remainder (P = .08). On multivariate analysis of relapse parameters available in 104 patients, high risk conferred short PRS (hazard ratio = 4.00, P < .001, R2 = 33%), whereas relapse hyperdiploidy predicted long PRS (hazard ratio = 0.37, P = .022, cumulative R2 = 41%). In case the initial partial response lasted less than 2 years, relapse low-risk identi-fied 26 patients with superior 3-year PRS of 61% versus 9% among 32 with relapse high-risk (P < .001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma.

Original languageEnglish (US)
Pages (from-to)3572-3575
Number of pages4
JournalBlood
Volume113
Issue number26
DOIs
StatePublished - 2009

Fingerprint

Gene Expression Profiling
Multiple Myeloma
Gene expression
Transplantation
Plasmas
Recurrence
Survival
Therapeutics
Hazards
Polyploidy
Multivariate Analysis

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Nair, B., Shaughnessy, J. D., Zhou, Y., Astrid-Cartron, M., Qu, P., Van Rhee, F., ... Barlogie, B. (2009). Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood, 113(26), 3572-3575. https://doi.org/10.1182/blood-2009-02-207803

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. / Nair, Bijay; Shaughnessy, John D.; Zhou, Yiming; Astrid-Cartron, Marie; Qu, Pingping; Van Rhee, Frits; Anaissie, Elias; Alsayed, Yazan; Waheed, Sarah; Hollmig, Klaus; Szymonifka, Jackie; Petty, Nathan; Hoering, Antje; Barlogie, Bart.

In: Blood, Vol. 113, No. 26, 2009, p. 3572-3575.

Research output: Contribution to journalArticle

Nair, B, Shaughnessy, JD, Zhou, Y, Astrid-Cartron, M, Qu, P, Van Rhee, F, Anaissie, E, Alsayed, Y, Waheed, S, Hollmig, K, Szymonifka, J, Petty, N, Hoering, A & Barlogie, B 2009, 'Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival', Blood, vol. 113, no. 26, pp. 3572-3575. https://doi.org/10.1182/blood-2009-02-207803
Nair, Bijay ; Shaughnessy, John D. ; Zhou, Yiming ; Astrid-Cartron, Marie ; Qu, Pingping ; Van Rhee, Frits ; Anaissie, Elias ; Alsayed, Yazan ; Waheed, Sarah ; Hollmig, Klaus ; Szymonifka, Jackie ; Petty, Nathan ; Hoering, Antje ; Barlogie, Bart. / Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. In: Blood. 2009 ; Vol. 113, No. 26. pp. 3572-3575.
@article{f1520dda79724e0fb99b9a037e3938f2,
title = "Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival",
abstract = "We report on prognostic implications for postrelapse survival (PRS) of a gene expression profiling (GEP)-defined risk score at relapse available in 120 myeloma patients previously enrolled in tandem transplantation trial Total Therapy 2. Among the 71 patients with additional GEP baseline information, 3-year PRS was 71{\%} in 40 patients with low risk present both at baseline and relapse contrasting with only 17{\%} in 28 patients with high risk at relapse, 12 of whom with baseline low-risk status fared better than the remainder (P = .08). On multivariate analysis of relapse parameters available in 104 patients, high risk conferred short PRS (hazard ratio = 4.00, P < .001, R2 = 33{\%}), whereas relapse hyperdiploidy predicted long PRS (hazard ratio = 0.37, P = .022, cumulative R2 = 41{\%}). In case the initial partial response lasted less than 2 years, relapse low-risk identi-fied 26 patients with superior 3-year PRS of 61{\%} versus 9{\%} among 32 with relapse high-risk (P < .001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma.",
author = "Bijay Nair and Shaughnessy, {John D.} and Yiming Zhou and Marie Astrid-Cartron and Pingping Qu and {Van Rhee}, Frits and Elias Anaissie and Yazan Alsayed and Sarah Waheed and Klaus Hollmig and Jackie Szymonifka and Nathan Petty and Antje Hoering and Bart Barlogie",
year = "2009",
doi = "10.1182/blood-2009-02-207803",
language = "English (US)",
volume = "113",
pages = "3572--3575",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

AU - Nair, Bijay

AU - Shaughnessy, John D.

AU - Zhou, Yiming

AU - Astrid-Cartron, Marie

AU - Qu, Pingping

AU - Van Rhee, Frits

AU - Anaissie, Elias

AU - Alsayed, Yazan

AU - Waheed, Sarah

AU - Hollmig, Klaus

AU - Szymonifka, Jackie

AU - Petty, Nathan

AU - Hoering, Antje

AU - Barlogie, Bart

PY - 2009

Y1 - 2009

N2 - We report on prognostic implications for postrelapse survival (PRS) of a gene expression profiling (GEP)-defined risk score at relapse available in 120 myeloma patients previously enrolled in tandem transplantation trial Total Therapy 2. Among the 71 patients with additional GEP baseline information, 3-year PRS was 71% in 40 patients with low risk present both at baseline and relapse contrasting with only 17% in 28 patients with high risk at relapse, 12 of whom with baseline low-risk status fared better than the remainder (P = .08). On multivariate analysis of relapse parameters available in 104 patients, high risk conferred short PRS (hazard ratio = 4.00, P < .001, R2 = 33%), whereas relapse hyperdiploidy predicted long PRS (hazard ratio = 0.37, P = .022, cumulative R2 = 41%). In case the initial partial response lasted less than 2 years, relapse low-risk identi-fied 26 patients with superior 3-year PRS of 61% versus 9% among 32 with relapse high-risk (P < .001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma.

AB - We report on prognostic implications for postrelapse survival (PRS) of a gene expression profiling (GEP)-defined risk score at relapse available in 120 myeloma patients previously enrolled in tandem transplantation trial Total Therapy 2. Among the 71 patients with additional GEP baseline information, 3-year PRS was 71% in 40 patients with low risk present both at baseline and relapse contrasting with only 17% in 28 patients with high risk at relapse, 12 of whom with baseline low-risk status fared better than the remainder (P = .08). On multivariate analysis of relapse parameters available in 104 patients, high risk conferred short PRS (hazard ratio = 4.00, P < .001, R2 = 33%), whereas relapse hyperdiploidy predicted long PRS (hazard ratio = 0.37, P = .022, cumulative R2 = 41%). In case the initial partial response lasted less than 2 years, relapse low-risk identi-fied 26 patients with superior 3-year PRS of 61% versus 9% among 32 with relapse high-risk (P < .001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma.

UR - http://www.scopus.com/inward/record.url?scp=70449496661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449496661&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-02-207803

DO - 10.1182/blood-2009-02-207803

M3 - Article

VL - 113

SP - 3572

EP - 3575

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -